JMP maintains $19 target on Aura Biosciences stock after FDA insights

JMP Securities reiterated a Market Outperform rating with a $19 price target for Aura Biosciences (AURA), citing the potential of its bel-sar treatment in both uveal melanoma and non-muscle invasive bladder cancer (NMIBC). The analyst views the recent FDA advisory committee's divided vote on UroGen Pharma's competing bladder cancer drug, UGN-102, as potentially beneficial for Aura, given the unmet medical need in NMIBC and bel-sar's differentiated mechanism; however, Aura must demonstrate convincing efficacy in its ongoing Phase 1b/2 trial, with results expected around the end of 2025. Despite a higher-than-anticipated net loss of $29 million in the first quarter, Aura maintains a strong cash position, further bolstered by a recent $75 million public offering, allowing it to advance its clinical programs.

Analysis

JMP Securities maintained its Market Outperform rating and a $19.00 price target for Aura Biosciences (AURA), reflecting significant potential upside, despite InvestingPro's assessment that the stock currently trades above its Fair Value. This optimism is partly fueled by the recent FDA advisory committee's divided 5-4 vote on UroGen Pharma's competing NMIBC drug, UGN-102, where concerns were raised about the lack of a randomized pivotal trial and challenges in interpreting data on response durability and recurrence risk. The FDA's recognition of an unmet medical need in NMIBC is viewed positively for Aura, whose drug candidate, bel-sar, is in a Phase 1b/2 trial for both intermediate and high-risk NMIBC, with key efficacy results anticipated around the end of 2025. Bel-sar, with its dual mechanism combining direct cytotoxicity and immune-mediated effects, aims to address these FDA concerns and is also being evaluated for uveal melanoma in a Phase 3 CoMpass trial, a market projected to exceed $1 billion. Financially, Aura reported a Q1 net loss of $29 million, higher than anticipated, and operating expenses $5 million above consensus. However, the company holds a robust cash reserve of $199 million, expected to fund operations into H2 2026, further extended by a recent $75 million public offering. Despite a rapid cash burn noted by InvestingPro, which assigns Aura a 'FAIR' overall financial health score, its current ratio is a healthy 11.06 and it holds more cash than debt. JMP views the NMIBC opportunity, with an estimated 83,000 U.S. annual incidence, as additional value to Aura's $368.31 million market capitalization, and bel-sar as a potentially differentiated treatment that could replace TURBT. The stock's low beta of 0.43 suggests lower market volatility. JMP had previously adjusted Aura's target to $19 from $21 while reiterating the Market Outperform rating, citing positive Key Opinion Leader feedback on bel-sar's early trial results.

Key Decisions for Investors

• Investors should closely monitor upcoming clinical trial milestones, particularly the Phase 1b/2 NMIBC data for bel-sar expected around the end of 2025 and ongoing progress in the Phase 3 uveal melanoma trial, as these are critical catalysts for Aura's valuation.
• Careful attention should be paid to Aura's cash burn rate and capital management, given the Q1 net loss of $29 million and rapid cash consumption, despite the current cash runway extending into late 2026 or early 2027 following recent financing.
• Consider the divergence between JMP Securities' $19 price target, implying substantial upside, and InvestingPro's assessment that AURA is trading above its fair value, necessitating a thorough risk-reward analysis contingent on bel-sar's clinical success.
• Evaluate the potential market opportunity stemming from the challenges faced by UroGen's UGN-102, which could benefit bel-sar in NMIBC, contingent on Aura delivering strong efficacy and safety data from its trials.